The Inhibitors of a Proton Pomp (IPP) are among the most taken drugs and their reception is connected with emergence of side effects, including, bone fractures, a chronic renal failure and gastrointestinal (G) infections. Though during one recently conducted randomized controlled clinical research the majority of these expected complications was not confirmed, results showed that reception of IPP increased the probability of developing of intestinal infection by 33% once a day. Obviously, it is connected with IPP-indutsirovannoy a hypochlorhydria at which the ability of an organism to protection against the got bacteria and viruses is broken.
Heavy acute respiratory sindroma2 (SARS-CoV-2) currently does not know of influence of suppression of secretion of hydrochloric acid on a coronavirus, but earlier data showed that pH ⩽3 reduces contageousness of the similar SARS-CoV-1 virus.
As SARS-CoV-2 uses a receptor of angiotensin-converting enzyme-2 for fast hit in enterocytes and replications in them, increase in level of acidity of a stomach of pH> 3 as a result of reception of IPP can facilitate penetration of a virus into a GIT that can lead to development of enteritis, colitis and further spread of a virus to other bodies, including lungs. On the basis of it it is quite possible that IPP can increase risk of infection of COVID-19.
Work during which conducted demographic examination online was carried out. The received messages about positive takes of the test for COVID-19 were then are processed by means of model of logistic regression with multiple variables for adjustment taking into account the wide range of the distorting factors. From 53,130 participants of research 3386 (6.4%) of people reported about positive takes of the test for COVID-19. The regression analysis showed that at the persons accepting IPP once a day or more rare (OSH 2.15; 95% of DI, 1.90-2.44) or twice a day (OSH 3.67; 95% of DI, 2.93-4.60), the probability of the message about a positive take of the test for COVID-19 was significantly higher, than at the persons which were not accepting IPP. The persons accepting H2 blockers - histamine receptors, were not exposed to the increased risk.
Thus, the proof of existence of independent interrelation "dose effect" between intake of anti-secretory drugs and confirmation of COVID-19 was revealed; the persons accepting IPP twice a day more likely have positive takes of the test in comparison with the persons accepting IPP once a day or more rare, and the persons accepting weaker blockers of H2 - histamine receptors, are not exposed to the increased risk.
Strengths of this research are that this first research such. As a result of the executed research the interrelation between reception of IPP and increase in risk of infection with the SARS-CoV-2 virus which gets into enterocytes and is replicated in them was established, and this fact coincides with provisions of earlier publications in which it was shown that drugs IPP also increase risk of infection with other intestinal infections. But in the majority of the previous researches impact of double administration of drugs was not considered. The interrelation between IPP and ZhK-manifestations of COVID-19 is also considered and it is established that reception of IPP also does not increase the probability of the message about such symptoms. As LCD symptoms prevail at respondents with COVID-19, carrying out further researches for the purpose of studying of the mechanisms which are the cornerstone of different manifestations of this disease is necessary.
At the same time, the research also has restrictions. First, this research is susceptible to residual distortion and a systematic error of selection; the persons with a severe form of a disease hospitalized with COVID-19, most likely, did not take part in this inspection. Secondly results of a research can also change depending on a protopathic systematic mistake as some participants could begin reception of IPP in response to certain symptoms of COVID-19. Thirdly, there is also a possible risk of systematic errors of the wrong classification and memory as data on intake of medicine and on test results on COVID-19 were provided by respondents. Fourthly, researchers did not define how at respondents the positive take of the test for COVID-19 was received, assessment of severity of a disease was also not executed. Fifthly, the majority of questions in a research concerned ZhK of symptoms, and respondents who had such symptoms could be more inclined to participation in poll. And, at last, there are restrictions in terms of an obobshchayemost as this examination was conducted only in English.
Thus it is possible to draw a conclusion that carrying out further researches of interrelation between intake of inhibitors of a proton pomp and COVID-19 is necessary.